endpts.com·Apr 13, 2026
The spring IPO cohort is emerging, with Seaport Therapeutics, a neuroscience drug developer, and Hemab Therapeutics, a biotech focused on blood clotting disorders, both filing for initial public offerings.
The recent IPO filings by Seaport Therapeutics and Hemab Therapeutics highlight a growing interest in specialized biotech sectors, particularly neuroscience drug development and blood clotting disorder treatments. For someone tracking biotech IPOs, these filings could signal emerging opportunities in niche therapeutic areas, suggesting a potential increase in investment and innovation in these fields.